Target- |
MechanismCell replacements |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
/ Not yet recruitingPhase 1IIT An Exploratory Study of REGEND003 Kidney Progenitor Cells on Patients With Type 2 Diabetes Mellitus (T2DM) and Chronic Kidney Disease (CKD)
100 Clinical Results associated with Regend Therapeutics (ShangHai)Co. Ltd.
0 Patents (Medical) associated with Regend Therapeutics (ShangHai)Co. Ltd.
100 Deals associated with Regend Therapeutics (ShangHai)Co. Ltd.
100 Translational Medicine associated with Regend Therapeutics (ShangHai)Co. Ltd.